|
Absence of sensation
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
However, with a similar level of anaesthesia effects and suitable parameters for mechanical ventilation, patients in the LMA group showed much more stability in the physiological indicators for inflammation and haemodynamics, including white blood cell count (ΔWBC) and percentage of neutrophil granulocytes (ΔNEU%) in the blood as well as heart rate (ΔHR) and mean arterial pressure (ΔMAP).
|
30069317 |
2018 |
|
Absence of sensation
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Following completion of treatment, MAP was determined in rats under anaesthesia via carotid artery cannulation.
|
28024836 |
2017 |
|
Acute pancreatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The body mass index and waist-hip ratio were correlated with the severity of acute pancreatitis (MAP, MSAP, and SAP), respiratory failure, and circulatory failure in HLAP (<i>p</i> < 0.05), but not correlated with the local complications (walled-off necrosis, pancreatic abscess, and pancreatic pseudocyst), renal failure, and gastrointestinal bleeding.The body mass index and waist-hip ratio are valuable in predicting severity and complication in HLAP.
|
28331492 |
2017 |
|
Acute Promyelocytic Leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, the anti-inflammatory effects of DA on the MAP kinase and NFκB signaling pathways and the expression of pro-inflammatory cytokines were investigated in phorbol 12-myristate 13-acetate (PMA)-activated human promyelocytic leukemia (HL-60) and lipopolysaccharide (LPS)-stimulated macrophage (Raw 264.7) cell lines.
|
30060484 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The present study demonstrates that, in the two acute promyelocytic leukemia (APL) cell lines NB4 and KG1, exhibiting distinct responsiveness to retinoic acids (RAs), IEX-1 expression is rapidly (30-60 min) induced by all-trans- or cis-RA and independently of other signal transduction mediators, such as TNFalpha, NF-kappaB or MAP kinases.
|
15306824 |
2004 |
|
Adenocarcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The results indicate that EGFR autocrine loop activity in adenocarcinoma may have alternative signaling activities aside from the activation of ras-MAP kinase pathway.
|
10963846 |
2000 |
|
Adenocarcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas.
|
21307665 |
2011 |
|
Adenocarcinoma of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
We studied the effects of echistatin (a well-known disintegrin) and thrombin (a serine protease capable of activation of integrin α(2)β(1) receptor) on prolidase activity and expressions of prolidase, α(2)β(1)-integrin receptor, focal adhesion kinase (FAK), MAP-kinases (ERK(1) and ERK(2)), and nuclear HIF-1α in human colon adenocarcinoma (DLD-1) cells.
|
21993963 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
The kinase defective EPHB6 receptor tyrosine kinase activates MAP kinase signaling in lung adenocarcinoma.
|
19513565 |
2009 |
|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas.
|
21307665 |
2011 |
|
Adenomatous Polyposis Coli
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
There are two major hereditary colorectal cancer syndromes: Adenomatous Polyposis, secondary to APC germline alterations (FAP, Familial Adenomatous Polyposis) or secondary to MUTYH germline alterations (MAP, MUTYH associated Polyposis), and Lynch syndrome, associated with germline mutations in mismatch repair genes (MLH1, MSH2, MSH6 and PMS2).
|
19931546 |
2010 |
|
Adenomatous Polyposis Coli
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The past 20 years has seen the discovery genes for familial adenomatous polyposis (FAP), its variant forms (attenuated FAP and the recessive MYH-associated polyposis or MAP), nonadenomatous polyposes, and hereditary nonpolyposis CRC (HNPCC).
|
17947820 |
2007 |
|
Adult Glioblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma.
|
21406405 |
2011 |
|
Adult Glioblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Expression Profiling of the MAP Kinase Phosphatase Family Reveals a Role for DUSP1 in the Glioblastoma Stem Cell Niche.
|
28822081 |
2017 |
|
Adult Glioblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era.
|
23115159 |
2013 |
|
Adult Pilocytic Astrocytoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Activation of the MAP Kinase (MAPK) pathway caused by the BRAFV600E mutation or the KIAA1549-BRAF fusion has been reported in pediatric GG and PA, respectively.
|
25524464 |
2014 |
|
Advanced Melanoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Therapies targeting immune checkpoints (CTLA-4) and the MAP kinase signaling pathway (RAS/RAF/MEK/ERK) have transformed the treatment of advanced melanoma in the past year.
|
22876817 |
2012 |
|
Advanced Melanoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Since patients diagnosed with BRAF V600E and V600K mutated advanced melanoma show response to treatment with MAP kinase inhibitors, several sensitive methods have been developed to determine the V600 allele status of melanoma patients.
|
25037456 |
2014 |
|
Advanced Melanoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Recent approaches targeting the oncogenic MAP kinase pathways have shown tremendous improvement in the overall survival of patients with advanced melanoma.
|
28928884 |
2017 |
|
Advanced Melanoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Immune checkpoint inhibitors and MAP kinase pathway-targeted therapies have revolutionized the management of advanced melanoma, and significantly prolong the overall survival of patients with this disease.
|
28914644 |
2017 |
|
Advanced Melanoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
|
26684394 |
2016 |
|
Age related macular degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
Since the secretion of VEGF by HRPE is regulated by MAP kinase pathways, MAP kinase inhibitors may have potential use as therapeutic agents for CNV in AMD.
|
14566975 |
2003 |
|
Alzheimer's Disease
|
0.070 |
Biomarker
|
disease |
BEFREE |
Alzheimer disease (AD) and related tauopathies are histopathologically characterized by a specific type of slow and progressive neurodegeneration, which involves the abnormal hyperphosphorylation of the microtubule associated protein (MAP) tau.
|
19184068 |
2009 |
|
Alzheimer's Disease
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Stress-responsive MAP kinase pathways were activated in the brain of the Tg2576/PS1(P264L) AD model, and this activation was coincident with the age-dependent increase in amyloid deposition, tau phosphorylation, and loss of synaptophysin.
|
11978814 |
2002 |
|
Alzheimer's Disease
|
0.070 |
Biomarker
|
disease |
BEFREE |
The dysregulation of posttranslational modifications of the microtubule-associated protein (MAP) tau plays a key role in Alzheimer's disease (AD) and related disorders.
|
28844006 |
2017 |